P A Bailey

Learn More
The potent and selective dopamine D-2 agonist, MK-458 [PHNO; (+)-4-propyl-9-hydroxynaphthoxazine] was administered as monotherapy to nine patients with Parkinson's disease in a double-blind, placebo-controlled 12-week investigation; ten other patients were randomized to placebo. MK-458 was formulated as a controlled-release preparation, using a(More)
Adjunctive treatment with the very potent and selective dopamine D-2 agonist MK-458 (controlled-release formulation) improved the control of parkinsonism in patients with fluctuating responses to levodopa therapy (with carbidopa). We subsequently switched patients to adjunctive treatment with pergolide, a less potent D-2 agonist. Pergolide therapy(More)
1. Four putative glutamate antagonists (L-glutamate diethyl ester, L-glutamate dimethyl ester, L-proline and 1-hydroxy-3-amino-pyrrolidone-2) were tested on the isolated hemisected toad spinal cord. 2. 1-hydroxy-3-amino-pyrrolidone-2 (10(-3)-10(-2) M) selectively antagonized the depolarizations evoked in both dorsal and ventral roots by applications of(More)
  • 1